136 related articles for article (PubMed ID: 36820722)
1. Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer.
Yetişir AE; Paydaş S; Büyükşimşek M; Oğul A; Yaprak Ö; Zorludemir S; Ergin M; Kolsuz İ; Kidi MM
Rev Assoc Med Bras (1992); 2023; 69(1):153-158. PubMed ID: 36820722
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between Expression of Runt-related Transcription Factor 3 and Enhancer of zeste Homolog 2 Proteins and Sensitivity to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer].
Yuan ZL; Wu XL; Qu M; Xue J; Han L; Sun GY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Dec; 43(6):856-864. PubMed ID: 34980322
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R
Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627
[TBL] [Abstract][Full Text] [Related]
4. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
5. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
11. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
14. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
15. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
17. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting pathological complete response after neoadjuvant chemotherapy in breast cancer: a single-center experience.
Mermut O; Inanc B; Gursu RU; Arslan E; Trabulus DC; Havare SB; Ulusan MB
Rev Assoc Med Bras (1992); 2021 Jun; 67(6):845-850. PubMed ID: 34709328
[TBL] [Abstract][Full Text] [Related]
19. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
